Epacadostat and Pembrolizumab in Patients With Head and Neck Cancer That Have Failed Prior Immunotherapy
Status:
Terminated
Trial end date:
2018-12-04
Target enrollment:
Participant gender:
Summary
Study to determine response rate of the combination of pembrolizumab plus epacadostat in
patients with head and neck cancers that have received prior immunotherapy.